Clinical Trial Update: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 trial of TTI-101 in participants with idiopathic pulmonary fibrosis, indicating the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• TTI-101

Snippet

Sponsor: Tvardi Therapeutics, Incorporated | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED